Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 6/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417012 | 0.95 | PLA2G7 (0.49) | PLA2G7ARPGRALDH1A1CYP2D6 | |
| SCHEMBL3419661 | 0.94 | AR (0.50) | PLA2G7ARALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL3414486 | 0.91 | AR (0.46) | PLA2G7ARPGRCYP2D6CYP2C9 | |
| SCHEMBL3419477 | 0.90 | AR (0.45) | PLA2G7ARPGRCYP2D6CYP2C9 | |
| SCHEMBL5140041 | 0.89 | AR (0.48) | ARPGRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3414201 | 0.89 | AR (0.49) | PLA2G7ARALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL3418840 | 0.88 | AR (0.45) | PLA2G7ARPGR | |
| SCHEMBL3416676 | 0.87 | AR (0.49) | ARPGRALDH1A1 | |
| SCHEMBL3417001 | 0.87 | PLA2G7 (0.47) | PLA2G7ARALDH1A1 | |
| SCHEMBL13070768 | 0.87 | AR (0.42) | PLA2G7ARPGRCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834063-B2 | 4-[(Cyclopropylmethyl)(2-{[4-(1,1-dimethylethyl)phenyl]oxy}ethyl)amino]-2-(trifluoromethyl)benzonitrile; modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors; osteoporosis, muscle wasting,endometriosis, cardiovascular disease; breast, uterine cancer, prostatic hyperplasia | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | claimed |
| US-20080255124-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | US | claimed |
| US-7834063-B2 | 4-[(Cyclopropylmethyl)(2-{[4-(1,1-dimethylethyl)phenyl]oxy}ethyl)amino]-2-(trifluoromethyl)benzonitrile; modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors; osteoporosis, muscle wasting,endometriosis, cardiovascular disease; breast, uterine cancer, prostatic hyperplasia | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834063-B2 | 4-[(Cyclopropylmethyl)(2-{[4-(1,1-dimethylethyl)phenyl]oxy}ethyl)amino]-2-(trifluoromethyl)benzonitrile; modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors; osteoporosis, muscle wasting,endometriosis, cardiovascular disease; breast, uterine cancer, prostatic hyperplasia | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080255124-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255124-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255124-A1 | Chemical Compounds | NR3C2, NR5A1, NR3C1 | PLA2G7 2046/4885AR 4/4885PGR 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.